Sonnet BioTherapeutics Holdings, Inc. (SONN)

SONN Cash Flow Statement

Financials in millions USD. Fiscal year is October - September.

Year Ending	TTM	Sep 30, 2023	Sep 30, 2022	Sep 30, 2021	Sep 30, 2020	Sep 30, 2019
Net Income	-8.43	-18.83	-29.72	-24.98	-65.6	-4.87
Depreciation & Amortization	0.08	0.08	0.09	0.1	0.06	0
Share-Based Compensation	0.21	0.25	0.88	1.38	0.37	0
Other Operating Activities	-4.96	-2.83	0.98	0.96	8.22	2.65
Operating Cash Flow	-13.1	-21.34	-27.77	-22.55	-15.61	-2.23
Capital Expenditures	0	0	0	-0	-0.08	0
Acquisitions	-0.44	-0.44	-0.81	0	0	0
Other Investing Activities	0.26	-	-	-	-	-
Investing Cash Flow	-0.18	-0.44	-0.81	-0	-0.08	0
Share Issuance / Repurchase	5.69	21.01	1.84	42.85	19.07	2.78
Debt Issued / Paid	-0	-0	0	-0.02	0.13	-0.53
Other Financing Activities	-0.02	-	2.17	-	3.81	-
Financing Cash Flow	5.68	21.01	4.01	42.83	23.01	2.26
Net Cash Flow	-7.6	-0.78	-24.57	20.27	7.31	0.03
Free Cash Flow	-13.1	-21.34	-27.77	-22.56	-15.69	-2.23
Free Cash Flow Margin	-14125.89%	-14439.19%	-7936.59%	-4663.91%	-	-
Free Cash Flow Per Share	-2.84	-20.56	-140.65	-283.01	-513.01	-128.18

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).